Technical Analysis for CARA - Cara Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Historical CARA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Death Cross | Bearish | 0.65% | |
| Down 3 Days in a Row | Weakness | 0.65% | |
| Overbought Stochastic | Strength | -2.51% | |
| New Downtrend | Bearish | -3.92% | |
| Upper Bollinger Band Walk | Strength | -3.92% | |
| Weak + Overbought | Other | -3.92% | |
| Overbought Stochastic | Strength | -3.92% | |
| Gapped Down | Weakness | -3.92% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible Inside Day | about 14 hours ago |
| Possible NR7 | about 14 hours ago |
| 60 Minute Opening Range Breakdown | about 17 hours ago |
| Up 2% | about 18 hours ago |
| Up 1% | about 18 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/10/2021
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat pain. Its products include intravenous CR845 that has completed Phase II clinical trials for the treatment of acute postoperative pain in adult patients; Oral CR845, which is in Phase I clinical trials to treat acute and chronic pain; and CR701 that is in preclinical trials for treating neuropathic and inflammatory pain. The company was founded in 2004 and is based in Shelton, Connecticut.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pain Clinical Trial Chronic Pain Amines Piperidines Mesoblast Acute And Chronic Pain
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pain Clinical Trial Chronic Pain Amines Piperidines Mesoblast Acute And Chronic Pain
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 29.6473 |
| 52 Week Low | 11.8 |
| Average Volume | 1,008,357 |
| 200-Day Moving Average | 16.85 |
| 50-Day Moving Average | 16.50 |
| 20-Day Moving Average | 13.83 |
| 10-Day Moving Average | 14.23 |
| Average True Range | 0.57 |
| ADX | 25.38 |
| +DI | 19.90 |
| -DI | 26.56 |
| Chandelier Exit (Long, 3 ATRs) | 13.28 |
| Chandelier Exit (Short, 3 ATRs) | 14.68 |
| Upper Bollinger Bands | 14.80 |
| Lower Bollinger Band | 12.86 |
| Percent B (%b) | 0.58 |
| BandWidth | 14.05 |
| MACD Line | -0.31 |
| MACD Signal Line | -0.55 |
| MACD Histogram | 0.2387 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 14.48 | ||||
| Resistance 3 (R3) | 14.49 | 14.34 | 14.40 | ||
| Resistance 2 (R2) | 14.34 | 14.21 | 14.34 | 14.37 | |
| Resistance 1 (R1) | 14.16 | 14.14 | 14.09 | 14.15 | 14.34 |
| Pivot Point | 14.01 | 14.01 | 13.97 | 14.00 | 14.01 |
| Support 1 (S1) | 13.83 | 13.88 | 13.75 | 13.81 | 13.62 |
| Support 2 (S2) | 13.68 | 13.80 | 13.67 | 13.59 | |
| Support 3 (S3) | 13.49 | 13.68 | 13.56 | ||
| Support 4 (S4) | 13.48 |
